Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Presacral Nerve Block vs Sham Block for Post-operative Pain in Total Laparoscopic Hysterectomy
NCT05953766Phase 2
Key facts
- Status
- Recruiting
- Start
- Sep 2025
- Primary completion
- Jul 2026
- Countries
- 1
- Sponsor
- Mount Sinai Hospital
- Modality
- Orthosteric Ligands
- Drugs
- ropivacaine
- Conditions
- postoperative pain
01
Overview
Phase 2, randomised, triple-blind trial of ropivacaine in postoperative pain (2 arms), sponsored by Mount Sinai Hospital. Primary endpoint: Early post-operative pain at 3 hours following surgery. Started Sep 2025; status: recruiting.
02
Design
2 arms- Study design
- RandomizedTriple-blind
Presacral Nerve Block
20mL of local ropivacaine 5.0mg/ml instilled in the presacral space
Sham Block
20mL of normal saline instilled in the presacral space
03
Who it enrols
Women aged 18 and older undergoing total laparoscopic hysterectomy, excluding those with BMI > 50, gynecological cancer beyond stage 1, chronic opioid use, fibromyalgia, or previous presacral neurectomy.
04
Endpoints
Primary
Early post-operative pain at 3 hours following surgery
Secondary
Post-operative pain at other time points
Beyond the preview
Go deeper on NCT05953766.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05953766.